About
Editorial policy
The rules every page follows: primary sources only, routes kept separate, no dosing or self-use guidance, human review before publishing.
By the GHK-Cu Peptide editorial team · Last reviewed · Editorial review: pending
Sources
- Primary research indexed in PubMed, chemical databases (PubChem, FDA GSRS) and regulators’ own documents.
- No invented studies, outcomes, citations or safety findings. If a source cannot be verified, the claim is not published.
- Secondary reports are used only where no primary document is available, and are labelled as secondary.
What we will not publish
- Doses, schedules, protocols, routes, timing, or preparation or administration instructions for any person.
- Conversions of animal or cell-study amounts into human amounts.
- Statements that GHK-Cu is safe, effective or proven in people for any use, or for any route other than the one a study actually tested.
- Recommendations to combine (“stack”) GHK-Cu with other substances, or to choose one product, form or route over another.
- Personal medical advice of any kind.
How findings are written
Study summaries name the model and report what was measured. Animal and cell findings are always labelled as such. Topical, cell, animal and other-route evidence is never pooled. Benefit-style questions are answered by tracing each topic to what was measured, in what model, with its grade (see benefit claims).
Review and approval
Every study record, regulatory source and related-resource link must be approved by a named reviewer before the production site will build. Material scientific or regulatory changes go through the same review. Pages display their review state.